A Diagnostic Imaging Study of 64Cu-SARTATE™ for Neuroendocrine Tumours


We probably should start to use the term “Somatostatin Receptor PET” (SSTR PET) a bit more.  We got used to using the term Ga68 PET but since then we have an approved copper version known as 64Cu Dotatate (commercial brand name in US DETECTNET™).  Now we have another in the clinical trial pipeline and will add others as they come onto my radar.

Ga68 Dotatate/TOC/NOC – click here
Cu64 Dotatate (DetectNET) – click here

A Diagnostic Imaging Study of 64Cu-SARTATE™ Using Positron Emission Tomography (PET) on Patients With Known or Suspected NETs

Reference: NCT04438304

Trial status: Recruiting

The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) NETs as a potential new way to help diagnose this type of cancer.

63 patient multicentre study run in Australia.

Clinical sites:

  • Royal North Shore Hospital
  • Peter MacCallum Cancer Centre
  • Royal Adelaide Hospital

How does it compare to Ga68 Dotatate?

Site: Peter MacCallum Cancer Centre,
Principal Investigator: Prof Rod Hicks

In comparison to 68Ga-DOTATATE scans, 64Cu-SARTATETM imaging in participants with NETs was equivalent at 1 hour, and superior at 4 hours, allowing detection of additional tumours at later time points.

Read more about SARTATE here.

Theranostics.  High late-retention in tumour and clearance from the liver suggests suitability for diagnostic studies as well as for prospective dosimetry for 67Cu-SARTATE PRRT (as at Apr 2021, being trialled with Neuroblastoma)

If you can see it, you can detect it.  Read more about Neuroendocrine Neoplasms imaging. 

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 


Thanks for reading.


Personal Facebook. Like this page please.
Blog Facebook. Like this page please.
Awareness Facebook Like this page please.

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


I love comments - feel free!

%d bloggers like this:
Verified by MonsterInsights